Premium
P2‐148: Neuropsychiatric symptom profiles in Mild Cognitive Impairment and Alzheimer's disease
Author(s) -
Woo Ellen,
Lu Po H.,
Grill Joshua,
Cummings Jeffrey L.
Publication year - 2010
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2010.05.1195
Subject(s) - irritability , apathy , disinhibition , psychology , mood , anxiety , psychiatry , clinical psychology , depression (economics) , psychosis , alzheimer's disease , dementia , disease , cognition , medicine , economics , macroeconomics
Test (UPSIT). Results: Smell identification was significantly impaired in the FTD-bv (p < 0,001) compared to the control group. There was no statistically significant difference between the PSP and the control group (p > 0,05) and between the naMCI and the control group (p > 0,05). Considering the small number of subjects in CBD and PPA subgroups, statistical analysis was meanwhile unable to be performed in these groups. Conclusions: Smell identification was impaired in the FTD-bv group and intact in the PSP group which is in correspondence with the previous studies. We found no smell identification deficit in the naMCI group which disables screening potential of smell testing in at risk of non-AD dementia individuals. Unlike in AD it cannot be used for dementia prediction among MCI population. FTLD patients represent heterogeneous group what is reflected even in smell identification. Our findings underlies appropriateness to deal with FTLD subgroups in clinical setting differently as this clinical syndrome may reflect various underlying pathophysiological processes. Usefulness of non-amnestic MCI concept should be challenged in these circumstances.